Global Pharmacovigilance Market Size, Share & Trends Analysis Report by Product Life Cycle, Service Provider (In-house, Contract Outsourcing), Type, Therapeutic Area, Process Flow, End Use, Region, and Segment Forecasts, 2024-2030

1.1 Market Segmentation & Scope
1.1.1 Product Life Cycle
1.1.2 Service Provider
1.1.3 Type
1.1.4 Process Flow
1.1.5 Therapeutic Area
1.1.6 End Use
1.1.7 Regional Scope
1.1.8 Estimates and Forecast Timeline
1.2 Research Methodology
1.3 Information Procurement
1.3.1 Purchased Database:
1.3.2 GVR’s Internal Database
1.3.3 Secondary Sources
1.3.4 Primary Research:
1.3.5 Details Of Primary Research
1.3.5.1 Data for primary interviews in North America
1.3.5.2 Data for Primary Interviews in Europe
1.3.5.3 Data for Primary Interviews in Asia Pacific
1.3.5.4 Data for Primary Interviews in Latin America
1.3.5.5 Data for Primary Interviews in Middle East & Africa
1.4 Information or Data Analysis
1.4.1 Data Analysis Models
1.5 Market Formulation & Validation
1.6 Model Details
1.6.1 Commodity Flow Analysis
1.6.1.1 Top down market estimation
1.6.1.2 CAGR Calculation
1.6.1.3 Key Report Updates
1.7 List of Secondary Sources
1.8 List of Abbreviations
1.9 Market Definitions
1.10 Report Objectives
1.10.1 Objective 1:
1.10.2 Objective 2:

2.1 Market Snapshot
2.2 Segment Snapshot (Product Life Cycle & Service Provider)
2.3 Segment Snapshot (Type & Therapeutic Area)
2.4 Segment Snapshot (Process Flow & End Use)
2.5 Competitive Landscape Snapshot

3.1 Market Lineage Outlook
3.1.1 Parent Market Analysis
3.1.2 Ancillary Market Analysis
3.2 Penetration & Growth Prospect Mapping
3.3 Pharmacovigilance Market Dynamics
3.3.1 Market Driver Analysis
3.3.1.1 Growing drug consumption and drug development rates
3.3.1.2 Increasing incidence of ADR and drug toxicity
3.3.1.3 Increasing trend of outsourcing pharmacovigilance services
3.3.1.4 Increasing externalization of clinical trial studies by large pharmaceutical and biopharmaceutical companies
3.3.1.5 Increasing regulatory Burden on Manufacturers
3.3.1.6 Introduction of technologically advanced software services
3.3.1.7 Constantly rising investment on R&D by healthcare companies
3.3.1.8 Partnerships and collaborations between market players
3.3.2 Market Restraint Analysis
3.3.2.1 Shortage of skilled labor
3.3.2.2 Expensive technology for small and mid-sized player
3.3.2.3 Lack of recognition
3.3.2.4 Scarcity of integration standards
3.3.3 Industry Challenges
3.4 Pharmacovigilance Market Analysis Tools: Porters
3.5 SWOT Analysis, by Factor (Political & Legal, Economic, and Technological)
3.6 Value Chain Analysis
3.6.1 Preclinical
3.6.2 Clinical
3.6.3 PMA
3.7 Mapping of Life Cycle against Service Offering and Their Demand
3.8 Regulatory Framework
3.8.1 List of Regulatory Bodies by Country
3.9 Organization Structure Introduction
3.10 Pricing Models
3.10.1 Drug Safety Budget Allocation by Activities
3.10.2 By Development Phase
3.10.3 By Therapeutic Area
3.10.4 Pricing Level
3.10.4.1 Project management
3.10.4.2 Case processing
3.10.4.3 ADR Reporting
3.10.4.4 Medical writing
3.10.4.5 Drug safety management
3.11 Technology Timeline Overview
3.11.1 Changing Technology & Adoption
3.11.1.1 Social Media
3.11.1.2 Literature screening
3.11.1.3 Automation and AI
3.11.1.4 Big data analytics in PV
3.12 Impact of COVID-19
3.12.1 Recent Developments & Strategic Outcomes
3.12.1.1 Regulatory requirements/changes due to COVID-19
3.12.2 Strategies Implemented by Companies
3.12.2.1 IQVIA
3.12.2.2 PARAXEL International Corporation
3.12.2.3 Bioclinica
3.12.2.4 Pharmaceutical Product Development (PPD)
3.12.2.5 IBM Corporation
3.12.2.6 ICON, plc
3.12.2.7 PRA Health Sciences
3.12.2.8 Covance Inc.
3.12.2.9 ArisGlobal
3.12.2.10 Linical Accelovance
3.12.2.11 Laboratory Corporation of America Holdings
3.13 Market Trends
3.13.1 Scaling Of Resources
3.13.2 Automation in Pharmacovigilance
3.14 Impact of Inflation
3.15 Comparative Analysis between Medical Writing vs Medical Safety Review
3.15.1 Medical Writing Market Outlook, 2022
3.15.1.1 Medical writing Market estimates and forecasts, 2018-2030 (USD Million)
3.15.2 Medical Safety Review Market Outlook, 2022
3.15.2.1 Medical Safety Review market estimates and forecasts, 2018-2030 (USD Million)

4.1 Product Life Cycle Market Share Analysis, 2022 & 2030
4.2 Product Life Cycle Dashboard
4.3 Market definition and scope
4.3.1 Preclinical
4.3.1.1 Preclinical market estimates and forecasts, 2018-2030 (USD Million)
4.3.2 Phase I
4.3.2.1 Phase I market estimates and forecasts, 2018-2030 (USD Million)
4.3.3 Phase II
4.3.3.1 Phase II market estimates and forecasts, 2018-2030 (USD Million)
4.3.4 Phase III
4.3.4.1 Phase III market estimates and forecasts, 2018-2030 (USD Million)
4.3.5 Phase IV
4.3.5.1 Phase IV market estimates and forecasts, 2018-2030 (USD Million)

5.1 Service provider Market Share Analysis, 2023 & 2030
5.2 Service Provider Dashboard
5.3 Market definition and scope
5.3.1 IN HOUSE
5.3.1.1 In house market estimates and forecasts, 2018-2030 (USD Million)
5.3.2 Contract Outsourcing
5.3.2.1 Contract outsourcing market estimates and forecasts, 2018-2030 (USD Million)

6.1 Type Market Share Analysis, 2023 & 2030
6.2 Type Dashboard
6.3 Market definition and scope
6.3.1 Spontaneous Reporting
6.3.1.1 Spontaneous Reporting market estimates and forecasts, 2018-2030 (USD Million)
6.3.2 Intensified ADR Reporting
6.3.2.1 Intensified ADR Reporting market estimates and forecasts, 2018-2030 (USD Million)
6.3.3 Targeted Spontaneous Reporting
6.3.3.1 Targeted spontaneous reporting market estimates and forecasts, 2018-2030 (USD Million)
6.3.4 Cohort Event Monitoring (CEM)
6.3.4.1 CEM market estimates and forecasts, 2018-2030 (USD Million)
6.3.5 EHR Mining
6.3.5.1 EHR Mining market estimates and forecasts, 2018-2030 (USD Million)

7.1 Process Flow Market Share Analysis, 2023 & 2030
7.2 Process Flow Dashboard
7.3 Market definition and scope
7.3.1 Case Data Management
7.3.1.1 Case data management market estimates and forecasts, 2018-2030 (USD Million)
7.3.1.1.1 Case logging
7.3.1.1.1.1 Case logging market estimates and forecasts, 2018-2030 (USD Million)
7.3.1.1.2 Case data analysis
7.3.1.1.2.1 Case data analysis market estimates and forecasts, 2018-2030 (USD Million)
7.3.1.1.3 Medical reviewing and reporting
7.3.1.1.3.1 Medical reviewing and reporting market estimates and forecasts, 2018-2030 (USD Million)
7.3.2 Signal Detection
7.3.2.1 Signal detection market estimates and forecasts, 2018-2030 (USD Million)
7.3.2.1.1 Adverse event logging
7.3.2.1.1.1 Adverse Event Logging market estimates and forecasts, 2018-2030 (USD Million)
7.3.2.1.2 Adverse Event Analysis
7.3.2.1.2.1 Adverse Event Analysis market estimates and forecasts, 2018-2030 (USD Million)
7.3.2.1.3 Adverse Event Review & Reporting
7.3.2.1.3.1 Adverse Event Review & Reporting market estimates and forecasts, 2018-2030 (USD Million)
7.3.3 Risk Management System
7.3.3.1 Risk Management System market estimates and forecasts, 2018-2030 (USD Million)
7.3.3.1.1 Risk Evaluation System
7.3.3.1.1.1 Risk Evaluation System market estimates and forecasts, 2018-2030 (USD Million)
7.3.3.1.2 Risk Mitigation System
7.3.2.1.2.1 Risk Mitigation System market estimates and forecasts, 2018-2030 (USD Million)

8.1 Therapeutic Area Market Share Analysis, 2023 & 2030
8.2 Therapeutic Area Dashboard
8.3 Market definition and scope
8.3.1 Oncology
8.3.1.1 Oncology market estimates and forecasts, 2018-2030 (USD Million)
8.3.2 Neurology
8.3.2.1 Neurology market estimates and forecasts, 2018-2030 (USD Million)
8.3.3 Cardiology
8.3.3.1 Cardiology market estimates and forecasts, 2018-2030 (USD Million)
8.3.4 Respiratory Systems
8.3.4.1 Respiratory systems market estimates and forecasts, 2018-2030 (USD Million)
8.3.5 Others
8.3.5.1 Others market estimates and forecasts, 2018-2030 (USD Million)

9.1 End Use Market Share Analysis, 2023 & 2030
9.2 End Use Dashboard
9.3 Market definition and scope
9.3.1 Pharmaceuticals
9.3.1.1 Pharmaceuticals market estimates and forecasts, 2018-2030 (USD Million)
9.3.2 Biotechnology Companies
9.3.2.1 Biotechnology companies market estimates and forecasts, 2018-2030 (USD Million)
9.3.3 Medical Device Manufacturers
9.3.3.1 Medical Device Manufacturers market estimates and forecasts, 2018-2030 (USD Million)
9.3.4 Others
9.3.4.1 Others market estimates and forecasts, 2018-2030 (USD Million)

10.1 Regional Market Snapshot
10.2 North America
10.2.1 North America Pharmacovigilance Market Estimates and Forecasts, 2018-2030 (USD Million)
10.2.2 U.S.
10.2.2.1 U.S. Pharmacovigilance market estimates and forecasts, 2018- 2030 (USD Million)
10.2.2.2 Competitive scenario
10.2.2.3 Regulatory Framework
10.2.3 Canada
10.2.3.1 Canada Pharmacovigilance market estimates and Forecasts, 2018-2030 (USD Million)
10.2.3.2 Competitive scenario
10.2.3.3 Regulatory Framework
10.3 Europe
10.3.1 Europe Pharmacovigilance Market Estimates and Forecasts, 2018-2030 (USD Million)
10.3.2 UK
10.3.2.1 UK Pharmacovigilance market estimates and Forecasts, 2018-2030 (USD Million)
10.3.2.2 Competitive scenario
10.3.2.3 Regulatory Framework
10.3.3 Germany
10.3.3.1 Germany Pharmacovigilance market estimates and forecasts, 2018-2030 (USD Million
10.3.3.2 Competitive scenario
10.3.3.3 Regulatory Framework
10.3.4 France
10.3.4.1 France Pharmacovigilance market estimates and forecasts, 2018- 2030 (USD Million)
10.3.4.2 Competitive scenario
10.3.4.3 Regulatory Framework
10.3.5 Italy
10.3.5.1 Italy Pharmacovigilance market estimates and forecasts, 2018-2030 (USD Million)
10.3.5.2 Competitive scenario
10.3.5.3 Regulatory Framework
10.3.6 Spain
10.3.6.1 Spain pharmacovigilance market estimates and forecasts, 2018-2030 (USD Million)
10.3.6.2 Competitive scenario
10.3.6.3 Regulatory Framework
10.3.7 Russia
10.3.7.1 Russia Pharmacovigilance market estimates and forecasts, 2018- 2030 (USD Million)
10.3.7.2 Competitive scenario
10.3.7.3 Regulatory Framework
10.3.8 Denmark
10.3.8.1 Denmark Pharmacovigilance Market Estimates and Forecasts, 2018-2030 (USD Million)
10.3.8.2 Competitive scenario
10.3.8.3 Regulatory Framework
10.3.9 Norway
10.3.9.1 Norway Pharmacovigilance Market Estimates and Forecasts, 2018-2030 (USD Million)
10.3.9.2 Competitive scenario
10.3.9.3 Regulatory Framework
10.3.10 Sweden
10.3.10.1 Sweden Pharmacovigilance Market Estimates and Forecasts, 2018-2030 (USD Million)
10.3.10.2 Competitive scenario
10.3.10.3 Regulatory Framework
10.4 Asia Pacific
10.4.1 Asia Pacific Pharmacovigilance Market Estimates and Forecasts, 2018-2030 (USD Million)
10.4.2 JAPAN
10.4.2.1 Japan Pharmacovigilance Market Estimates and Forecasts, 2018-2030 (USD Million)
10.4.2.2 Competitive scenario
10.4.2.3 Regulatory Framework
10.4.3 CHINA
10.4.3.1 China Pharmacovigilance Market Estimates and Forecasts, 2018-2030 (USD Million)
10.4.3.2 Competitive Scenario
10.4.3.3 Regulatory Framework
10.4.4 India
10.4.4.1 India Pharmacovigilance Market Estimates and Forecasts, 2018-2030 (USD Million)
10.4.4.2 Competitive Scenario
10.4.4.3 Regulatory Framework
10.4.5 Australia
10.4.5.1 Australia Pharmacovigilance Market Estimates and Forecasts, 2018-2030 (USD Million)
10.4.5.2 Competitive Scenario
10.4.5.3 Regulatory Framework
10.4.6 Thailand
10.4.6.1 Thailand Pharmacovigilance Market Estimates and Forecasts, 2018-2030 (USD Million)
10.4.6.2 Competitive Scenario
10.4.6.3 Regulatory Framework
10.4.7 South Korea
10.4.7.1 South Korea Pharmacovigilance Market Estimates and Forecasts, 2018-2030 (USD Million)
10.4.7.2 Competitive Scenario
10.4.7.3 Regulatory Framework
10.5 Latin America
10.5.1 Latin America Pharmacovigilance Market Estimates and Forecasts, 2018-2030 (USD Million)
10.5.2 Brazil
10.5.2.1 Brazil Pharmacovigilance Market Estimates and Forecasts, 2018-2030 (USD Million)
10.5.2.2 Competitive Scenario
10.5.2.3 Regulatory Framework
10.5.3 Mexico
10.5.3.1 Mexico Pharmacovigilance Market Estimates and Forecasts, 2018-2030 (USD Million)
10.5.3.2 Competitive Scenario
10.5.3.3 Regulatory Framework
10.5.4 Argentina
10.5.4.1 Argentina Pharmacovigilance Market Estimates and Forecasts, 2018-2030 (USD Million)
10.5.4.2 Competitive Scenario
10.5.4.3 Regulatory Framework
10.6 MEA
10.6.1 MEA Pharmacovigilance Market Estimates and Forecasts, 2018-2030 (USD Million)
10.6.2 South Africa
10.6.2.1 South Africa Pharmacovigilance Market Estimates and Forecasts, 2018-2030 (USD Million)
10.6.2.2 Competitive Scenario
10.6.2.3 Regulatory Framework
10.6.3 Saudi Arabia
10.6.3.1 Saudi Arabia Pharmacovigilance Market Estimates and Forecasts, 2018- 2030 (USD Million)
10.6.3.2 Competitive Scenario
10.6.3.3 Regulatory Framework
10.6.4 UAE
10.6.4.1 UAE Arabia Pharmacovigilance Market Estimates and Forecasts, 2018- 2030 (USD Million)
10.6.4.2 Competitive Scenario
10.6.4.3 Regulatory Framework
10.6.5 Kuwait
10.6.5.1 Kuwait Pharmacovigilance Market Estimates and Forecasts, 2018- 2030 (USD Million)
10.6.5.2 Competitive Scenario
10.6.5.3 Regulatory Framework

11.1 Market Participation Categorization
11.2 Public Companies
11.2.1 Company Market Position Analysis
11.2.2 Company Market Share
11.3 Private Companies
11.3.1 List of Key Emerging Companies
11.4 Competitive Factors and Strategies
11.4.1 Increasing strategic collaborations and product launch
11.4.2 Strategic Government initiatives which include collaborations
11.4.3 Competitors increased PV awareness program
11.4.4 Competitors increased collaboration and outsourcing of operations
11.4.5 Consolidation Trends
11.5 Healthcare Companies Using Pharmacovigilance Services
11.5.1 Potential Customers
11.5.2 Notable Cases
11.5.2.1 Case Study 1
11.5.2.1.1 Case Study 1
11.5.3.1.2 Case Study 2
11.5.2.2 Case Study 2
11.5.2.3 Case Study 3
11.5.3.4 Case Study 4
11.5.3 Key Focus areas for the pharmaceutical/healthcare companies
11.5.3.1 Adoption of technological advancements in life sciences industry
11.5.3.2 Published survey insights - related to adoption of pharmacovigilance automation

12.1 Company Profiles
12.1.1 ACCENTURE
12.1.1.1 Company overview
12.1.1.2 Service benchmarking
12.1.1.3 Financial performance
12.1.1.4 Strategic initiatives
12.1.1.5 SWOT Analysis
12.1.2 CLINQUEST GROUP B.V. (LINICAL AMERICAS)
12.1.2.1 Company overview
12.1.2.2 Service benchmarking
12.1.2.3 Financial performance
12.1.2.4 Strategic initiatives
12.1.2.5 SWOT Analysis
12.1.3 IQVIA Inc.
12.1.3.1 Company overview
12.1.3.2 Service benchmarking
12.1.3.3 Financial performance
12.1.3.4 Strategic initiatives
12.1.3.5 SWOT Analysis
12.1.4 COGNIZANT
12.1.4.1 Company overview
12.1.4.2 Service benchmarking
12.1.4.3 Financial performance
12.1.4.4 Strategic initiatives
12.1.4.5 SWOT Analysis
12.1.5 LABORATORY CORPORATION OF AMERICA HOLDINGS
12.1.5.1 Company overview
12.1.5.2 Service benchmarking
12.1.5.3 Financial performance
12.1.5.4 Strategic initiatives
12.1.5.5 SWOT Analysis
12.1.6 IBM
12.1.6.1 Company overview
12.1.6.2 Service benchmarking
12.1.6.3 Financial performance
12.1.6.4 Strategic initiatives
12.1.6.5 SWOT Analysis
12.1.7 ARISGLOBAL
12.1.7.1 Company Overview
12.1.7.2 Service Benchmarking
12.1.7.3 Financial Performance
12.1.7.4 Strategic Initiatives
12.1.7.5 SWOT Analysis
12.1.8 ICON PLC.
12.1.8.1 Company Overview
12.1.8.2 Service Benchmarking
12.1.8.3 Financial Performance
12.1.8.4 Strategic Initiatives
12.1.8.5 SWOT Analysis
12.1.9 CAPGEMINI
12.1.9.1 Company Overview
12.1.9.2 Service Benchmarking
12.1.9.3 Financial Performance
12.1.9.4 Strategic Initiatives
12.1.9.5 SWOT Analysis
12.1.10 ITCLINICAL
12.1.10.1 Company Overview
12.1.10.2 Service Benchmarking
12.1.10.3 Financial Performance
12.1.10.4 Strategic Initiatives
12.1.10.5 SWOT Analysis
12.1.11 TAKE SOLUTIONS LIMITED
12.1.11.1 Company Overview
12.1.11.2 Service Benchmarking
12.1.11.3 Financial Performance
12.1.11.4 Strategic Initiatives
12.1.11.5 SWOT Analysis
12.1.12 PAREXEL INTERNATIONAL CORPORATION.
12.1.12.1 Company Overview
12.1.12.2 Service Benchmarking
12.1.12.3 Financial Performance
12.1.12.4 Strategic Initiatives
12.1.12.5 SWOT Analysis
12.1.13 BIOCLINICA, INC.
12.1.13.1 Company overview
12.1.13.2 Service benchmarking
12.1.13.3 Financial performance
12.1.13.4 Strategic initiatives
12.1.13.5 SWOT Analysis
12.1.14 WIPRO
12.1.14.1 Company Overview
12.1.14.2 Service Benchmarking
12.1.14.3 Financial Performance
12.1.14.4 Strategic Initiatives
12.1.14.5 SWOT Analysis
12.1.15 UNITED BIOSOURCE LLC
12.1.15.1 Company Overview
12.1.15.2 Service Benchmarking
12.1.15.3 Financial Performance
12.1.15.4 Strategic initiatives
12.1.15.5 SWOT Analysis
12.1.16 FMD K&L (CLINCHOICE)
12.1.16.1 Company Overview
12.1.16.2 Service Benchmarking
12.1.16.3 Financial performance
12.1.16.4 Strategic initiatives
12.1.16.5 SWOT Analysis

13.1 Key Winning/Scoring Criteria
13.1.1 By Categories
13.1.1.1 Pharmaceuticals
13.1.1.2 Biotech companies
13.1.1.3 Medical device companies
13.2 Key Vendor Selection Factors
13.2.1 By Category
13.2.2 By Company Size
13.2.2.1 Key Takeaways

Table 1 List of secondary sources
Table 2 List of Abbreviation
Table 3 Types of ADRs
Table 4 Adverse Drug Events (ADEs) in hospitals
Table 5 Pharmacovigilance outsourcing services insights
Table 6 List of regulations, by country
Table 7 Estimated Total Per-Study Costs (in $ Millions), by Phase and Therapeutic Area
Table 8 Case management costing by year
Table 9 Price by case processing volume
Table 10 Subscription services for medical manuscript writing
Table 11 Total literature searches (2013-2022)
Table 12 Instances of failed phase I clinical trials for COVID-19 vaccine
Table 13 Recruiting phase II clinical trials for oncology
Table 14 Outsourcing trend observed in pharmaceutical companies
Table 15 Recent Market Events
Table 16 List of Major Deals & Acquisitions
Table 17 List of key distributors and channel partners
Table 18 List of key emerging companies’/technology disruptors/innovators
Table 19 North America Pharmacovigilance Market, by country, 2018-2030 (USD Million)
Table 20 North America Pharmacovigilance Market, by Injection Type, 2018-2030 (USD Million)
Table 21 North America Pharmacovigilance Market, by Anatomy, 2018-2030 (USD Million)
Table 22 North America Pharmacovigilance Market, by End Use, 2018-2030 (USD Million)
Table 23 U.S. Pharmacovigilance Market, by Injection Type, 2018-2030 (USD Million)
Table 24 U.S. Pharmacovigilance Market, by Anatomy, 2018-2030 (USD Million)
Table 25 U.S. Pharmacovigilance Market, by End Use, 2018-2030 (USD Million)
Table 26 Canada Pharmacovigilance Market, by Injection Type, 2018-2030 (USD Million)
Table 27 Canada Pharmacovigilance Market, by Anatomy, 2018-2030 (USD Million)
Table 28 Canada Pharmacovigilance Market, by End Use, 2018-2030 (USD Million)
Table 29 Europe Pharmacovigilance Market, by country, 2018-2030 (USD Million)
Table 30 Europe Pharmacovigilance Market, by Injection Type, 2018-2030 (USD Million)
Table 31 Europe Pharmacovigilance Market, by Anatomy, 2018-2030 (USD Million)
Table 32 Europe Pharmacovigilance Market, by End Use, 2018-2030 (USD Million)
Table 33 Germany Pharmacovigilance Market, by Injection Type, 2018-2030 (USD Million)
Table 34 Germany Pharmacovigilance Market, by Anatomy, 2018-2030 (USD Million)
Table 35 Germany Pharmacovigilance Market, by End Use, 2018-2030 (USD Million)
Table 36 UK Pharmacovigilance Market, by Injection Type, 2018-2030 (USD Million)
Table 37 UK Pharmacovigilance Market, by Anatomy, 2018-2030 (USD Million)
Table 38 UK Pharmacovigilance Market, by End Use, 2018-2030 (USD Million)
Table 39 France Pharmacovigilance Market, by Injection Type, 2018-2030 (USD Million)
Table 40 France Pharmacovigilance Market, by Anatomy, 2018-2030 (USD Million)
Table 41 France Pharmacovigilance Market, by End Use, 2018-2030 (USD Million)
Table 42 Italy Pharmacovigilance Market, by Injection Type, 2018-2030 (USD Million)
Table 43 Italy Pharmacovigilance Market, by Anatomy, 2018-2030 (USD Million)
Table 44 Italy Pharmacovigilance Market, by End Use, 2018-2030 (USD Million)
Table 45 Spain Pharmacovigilance Market, by Injection Type, 2018-2030 (USD Million)
Table 46 Spain Pharmacovigilance Market, by Anatomy, 2018-2030 (USD Million)
Table 47 Sapin Pharmacovigilance Market, by End Use, 2018-2030 (USD Million)
Table 48 Denmark Pharmacovigilance Market, by Injection Type, 2018-2030 (USD Million)
Table 49 Denmark Pharmacovigilance Market, by Anatomy, 2018-2030 (USD Million)
Table 50 Denmark Pharmacovigilance Market, by End Use, 2018-2030 (USD Million)
Table 51 Sweden Pharmacovigilance Market, by Injection Type, 2018-2030 (USD Million)
Table 52 Sweden Pharmacovigilance Market, by Anatomy, 2018-2030 (USD Million)
Table 53 Sweden Pharmacovigilance Market, by End Use, 2018-2030 (USD Million)
Table 54 Norway Pharmacovigilance Market, by Injection Type, 2018-2030 (USD Million)
Table 55 Norway Pharmacovigilance Market, by Anatomy, 2018-2030 (USD Million)
Table 56 Norway Pharmacovigilance Market, by End Use, 2018-2030 (USD Million)
Table 57 Asia Pacific Pharmacovigilance Market, by country, 2018-2030 (USD Million)
Table 58 Asia Pacific Pharmacovigilance Market, by Injection Type, 2018-2030 (USD Million)
Table 59 Asia Pacific Pharmacovigilance Market, by Anatomy, 2018-2030 (USD Million)
Table 60 Asia Pacific Pharmacovigilance Market, by End Use, 2018-2030 (USD Million)
Table 61 Japan Pharmacovigilance Market, by Injection Type, 2018-2030 (USD Million)
Table 62 Japan Pharmacovigilance Market, by Anatomy, 2018-2030 (USD Million)
Table 63 Japan Pharmacovigilance Market, by End Use, 2018-2030 (USD Million)
Table 64 China Pharmacovigilance Market, by Injection Type, 2018-2030 (USD Million)
Table 65 China Pharmacovigilance Market, by Anatomy, 2018-2030 (USD Million)
Table 66 China Pharmacovigilance Market, by End Use, 2018-2030 (USD Million)
Table 67 India Pharmacovigilance Market, by Injection Type, 2018-2030 (USD Million)
Table 68 India Pharmacovigilance Market, by Anatomy, 2018-2030 (USD Million)
Table 69 India Pharmacovigilance Market, by End Use, 2018-2030 (USD Million)
Table 70 Australia Pharmacovigilance Market, by Injection Type, 2018-2030 (USD Million)
Table 71 Australia Pharmacovigilance Market, by Anatomy, 2018-2030 (USD Million)
Table 72 Australia Pharmacovigilance Market, by End Use, 2018-2030 (USD Million)
Table 73 South Korea Pharmacovigilance Market, by End Use, 2018-2030 (USD Million)
Table 74 Thailand Pharmacovigilance Market, by Injection Type, 2018-2030 (USD Million)
Table 75 Thailand Pharmacovigilance Market, by Anatomy, 2018-2030 (USD Million)
Table 76 Thailand Pharmacovigilance Market, by End Use, 2018-2030 (USD Million)
Table 77 Latin America Pharmacovigilance Market, by country, 2018-2030 (USD Million)
Table 78 Latin America Pharmacovigilance Market, by Injection Type, 2018-2030 (USD Million)
Table 79 Latin America Pharmacovigilance Market, by Anatomy, 2018-2030 (USD Million)
Table 80 Latin America Pharmacovigilance Market, by End Use, 2018-2030 (USD Million)
Table 81 Brazil Pharmacovigilance Market, by Injection Type, 2018-2030 (USD Million)
Table 82 Brazil Pharmacovigilance Market, by Anatomy, 2018-2030 (USD Million)
Table 83 Brazil Pharmacovigilance Market, by End Use, 2018-2030 (USD Million)
Table 84 Mexico Pharmacovigilance Market, by Injection Type, 2018-2030 (USD Million)
Table 85 Mexico Pharmacovigilance Market, by Anatomy, 2018-2030 (USD Million)
Table 86 Mexico Pharmacovigilance Market, by End Use, 2018-2030 (USD Million)
Table 87 Argentina Pharmacovigilance Market, by Injection Type, 2018-2030 (USD Million)
Table 88 Argentina Pharmacovigilance Market, by Anatomy, 2018-2030 (USD Million)
Table 89 Argentina Pharmacovigilance Market, by End Use, 2018-2030 (USD Million)
Table 90 MEA Pharmacovigilance Market, by country, 2018-2030 (USD Million)
Table 91 MEA Pharmacovigilance Market, by Injection Type, 2018-2030 (USD Million)
Table 92 MEA Pharmacovigilance Market, by Anatomy, 2018-2030 (USD Million)
Table 93 MEA Pharmacovigilance Market, by End Use, 2018-2030 (USD Million)
Table 94 South Africa Pharmacovigilance Market, by Injection Type, 2018-2030 (USD Million)
Table 95 South Africa Pharmacovigilance Market, by Anatomy, 2018-2030 (USD Million)
Table 96 South Africa Pharmacovigilance Market, by End Use, 2018-2030 (USD Million)
Table 97 Saudi Arabia Pharmacovigilance Market, by Injection Type, 2018-2030 (USD Million)
Table 98 Saudi Arabia Pharmacovigilance Market, by Anatomy, 2018-2030 (USD Million)
Table 99 Saudi Arabia Pharmacovigilance Market, by End Use, 2018-2030 (USD Million)
Table 100 UAE Pharmacovigilance Market, by Injection Type, 2018-2030 (USD Million)
Table 101 UAE Pharmacovigilance Market, by Anatomy, 2018-2030 (USD Million)
Table 102 UAE Pharmacovigilance Market, by End Use, 2018-2030 (USD Million)
Table 103 Kuwait Pharmacovigilance Market, by Injection Type, 2018-2030 (USD Million)
Table 104 Kuwait Pharmacovigilance Market, by Anatomy, 2018-2030 (USD Million)
Table 105 Kuwait Pharmacovigilance Market, by End Use, 2018-2030 (USD Million)

Figure 1 Pharmacovigilance market segmentation
Figure 2 Market research process
Figure 3 Data triangulation techniques
Figure 4 Primary research pattern
Figure 5 Primary interviews in North America
Figure 6 Primary interviews in Europe
Figure 7 Primary interviews in APAC
Figure 8 Primary interviews in Latin America
Figure 9 Primary interviews in MEA
Figure 10 Market research approaches
Figure 11 Value-chain-based sizing & forecasting
Figure 12 QFD modeling for market share assessment
Figure 13 Market formulation & validation
Figure 14 Timeline of pharmacovigilance for a drug from development (premarket to post marketing)
Figure 15 Market Snapshot
Figure 16 Segment Snapshot (Product Life Cycle & Service Provider)
Figure 17 Segment Snapshot (Type & Therapeutic Area)
Figure 18 Segment Snapshot (Process Flow & End Use))
Figure 19 Competitive Landscape Snapshot
Figure 20 Penetration & growth prospect mapping
Figure 21 Pharmacovigilance market dynamics
Figure 22 Porter’s five force model
Figure 23 Pharmacovigilance - SWOT analysis, by factor (political & legal, economic, and technological)
Figure 24 Pharmacovigilance & Patient Safety Services - Product Life Cycle
Figure 25 PV department
Figure 26 PV organization structure
Figure 27 Estimated budget allocation of drug safety activities at global and country-level
Figure 28 Comparison between estimated global and country-level drug safety budget allocation
Figure 29 Average % of drug safety budget contributed by function at a global level
Figure 30 Pharmacovigilance system cost for small-sized firms and larger-sized firms
Figure 31 Clinical trial cost by phase (%)
Figure 32 Selected clinical trials costs based on technology
Figure 33 Estimated cost of developing therapeutic medical device in the U.S.
Figure 34 The average monthly cost of illness due to ADRs
Figure 35 Medical Writers Employers by Industry
Figure 36 Trending topics on social media (2017)
Figure 37 ADR detection and from social media data
Figure 38 Common literature automation tool flow
Figure 39 Automation processes in PV
Figure 40 Deterrents to Leveraging the Cloud (Oracle Survey)
Figure 41 The three-step process to compute signal statistics from search log using big data
Figure 42 Risk Management Capacity &Capability with Pharmacovigilance Using Big Data
Figure 43 Pharma & Biotech R&D expense growth, 2020 (%)
Figure 44 Medical writing market outlook, 2022 (USD Million)
Figure 45 Medical writing market, 2018-2030 (USD Million)
Figure 46 Global medical safety review market, 2018-2030 (USD Million)
Figure 47 Pharmacovigilance market: Product life cycle movement analysis
Figure 48 Pharmacovigilance market product life cycle dashboard
Figure 49 Global Preclinical market, 2018-2030 (USD Million)
Figure 50 Global Phase I market, 2018-2030 (USD Million)
Figure 51 Global Phase II market, 2018-2030 (USD Million)
Figure 52 Global Phase III market, 2018-2030 (USD Million)
Figure 53 Adverse events reported in FAERS system, 2019-2022
Figure 54 Global Phase IV market, 2018-2030 (USD Million)
Figure 55 Pharmacovigilance market: Service provider movement analysis
Figure 56 Pharmacovigilance Service provider dashboard
Figure 57 Global In-house market, 2018-2030 (USD Million)
Figure 58 Global contract outsourcing market, 2018-2030 (USD Million)
Figure 59 Pharmacovigilance market: Type movement analysis
Figure 60 Pharmacovigilance type dashboard
Figure 61 Global spontaneous reporting market, 2018-2030 (USD Million)
Figure 62 Global intensified ADR reporting market, 2018-2030 (USD Million)
Figure 63 Global targeted spontaneous reporting market, 2018-2030 (USD Million)
Figure 64 Global CEM market, 2018-2030 (USD Million)
Figure 65 Global EHR mining market, 2018-2030 (USD Million)
Figure 66 Pharmacovigilance market: Process flow movement analysis
Figure 67 Pharmacovigilance market process flow dashboard
Figure 68 Global case data management market, 2018-2030 (USD Million)
Figure 69 Global case logging market, 2018-2030 (USD Million)
Figure 70 Global case data analysis market, 2018-2030 (USD Million)
Figure 71 Global medical reviewing and reporting market, 2018-2030 (USD Million)
Figure 72 Global signal detection market, 2018-2030 (USD Million)
Figure 73 Global adverse event logging market, 2018-2030 (USD Million)
Figure 74 Global adverse event analysis market, 2018-2030 (USD Million)
Figure 75 Global adverse event review & reporting market, 2018-2030 (USD Million)
Figure 76 Global risk management system market, 2018-2030 (USD Million)
Figure 77 Global Risk Evaluation System market, 2018-2030 (USD Million)
Figure 78 Global risk mitigation system market, 2018-2030 (USD Million)
Figure 79 Pharmacovigilance market: Therapeutic area movement analysis
Figure 80 Pharmacovigilance market therapeutic area dashboard
Figure 81 Global oncology market, 2018-2030 (USD Million)
Figure 82 Global neurology market, 2018-2030 (USD Million)
Figure 83 Global cardiology market, 2018-2030 (USD Million)
Figure 84 Global respiratory systems market, 2018-2030 (USD Million)
Figure 85 Global others market, 2018-2030 (USD Million)
Figure 86 Pharmacovigilance market: End use movement analysis
Figure 87 Pharmacovigilance market end use dashboard
Figure 88 Global pharmaceuticals market, 2018-2030 (USD Million)
Figure 89 Global biotechnology companies’ market, 2018-2030 (USD Million)
Figure 90 Global medical device manufacturers market, 2018-2030 (USD Million)
Figure 91 Global others market, 2018-2030 (USD Million)
Figure 92 Regional market place: Key takeaways
Figure 93 North America pharmacovigilance market, 2018-2030 (USD Million)
Figure 94 U.S. key country dynamics (Part 1)
Figure 95 U.S. key country dynamics (Part 2)
Figure 96 U.S. pharmacovigilance market, 2018-2030 (USD Million)
Figure 97 Canada key country dynamics (Part 1)
Figure 98 Canada key country dynamics (Part 2)
Figure 99 Canada pharmacovigilance market, 2018-2030 (USD Million)
Figure 100 Europe pharmacovigilance market, 2018-2030 (USD Million)
Figure 101 UK key country dynamics (Part 1)
Figure 102 UK key country dynamics (Part 2)
Figure 103 UK pharmacovigilance market, 2018-2030 (USD Million)
Figure 104 Germany key country dynamics (Part 1)
Figure 105 Germany key country dynamics (Part 2)
Figure 106 Germany pharmacovigilance market, 2018-2030 (USD Million)
Figure 107 France key country dynamics (Part 1)
Figure 108 France key country dynamics (Part 2)
Figure 109 France pharmacovigilance market, 2018-2030 (USD Million)
Figure 110 Italy key country dynamics (Part 1)
Figure 111 Italy key country dynamics (Part 2)
Figure 112 Italy pharmacovigilance market, 2018-2030 (USD Million)
Figure 113 Spain key country dynamics (Part 1)
Figure 114 Spain key country dynamics (Part 2)
Figure 115 Spain pharmacovigilance market, 2018-2030 (USD Million)
Figure 116 Russia key country dynamics
Figure 117 Russia pharmacovigilance market, 2018-2030 (USD Million)
Figure 118 Denmark key country dynamics (Part 1)
Figure 119 Denmark key country dynamics (Part 2)
Figure 120 Denmark pharmacovigilance market estimates and forecasts, 2018-2030 (USD Million)
Figure 121 Norway key country dynamics (Part 1)
Figure 122 Norway key country dynamics (Part 2)
Figure 123 Norway pharmacovigilance market estimates and forecasts, 2018-2030 (USD Million)
Figure 124 Sweden key country dynamics (Part 1)
Figure 125 Sweden key country dynamics (Part 2)
Figure 126 Sweden pharmacovigilance market estimates and forecasts, 2018-2030 (USD Million)
Figure 127 Asia Pacific Pharmacovigilance market, 2018-2030 (USD Million)
Figure 128 Japan pharmacovigilance market, 2018-2030 (USD Million)
Figure 129 China key country dynamics (Part 1)
Figure 130 China key country dynamics (Part 2)
Figure 131 China pharmacovigilance market, 2018-2030 (USD Million)
Figure 132 India key country dynamics (Part 1)
Figure 133 India key country dynamics (Part 2)
Figure 134 India pharmacovigilance market, 2018-2030 (USD Million)
Figure 135 Australia pharmacovigilance market, 2018-2030 (USD Million)
Figure 136 Thailand key country dynamics (Part 1)
Figure 137 Thailand key country dynamics (Part 2)
Figure 138 Thailand pharmacovigilance market, 2018-2030 (USD Million)
Figure 139 South Korea pharmacovigilance market, 2018-2030 (USD Million)
Figure 140 Latin America pharmacovigilance market, 2018-2030 (USD Million)
Figure 141 Brazil pharmacovigilance market, 2018-2030 (USD Million)
Figure 142 Mexico key country dynamics
Figure 143 Mexico pharmacovigilance market, 2018-2030 (USD Million)
Figure 144 Argentina pharmacovigilance market, 2018-2030 (USD Million)
Figure 145 MEA pharmacovigilance market, 2018-2030 (USD Million)
Figure 146 South Africa pharmacovigilance market, 2018-2030 (USD Million)
Figure 147 Saudi Arabia pharmacovigilance market, 2018-2030 (USD Million)
Figure 148 UAE key country dynamics (Part 1)
Figure 149 UAE key country dynamics (Part 2)
Figure 150 UAE pharmacovigilance market, 2018-2030 (USD Million)
Figure 151 Kuwait pharmacovigilance market, 2018-2030 (USD Million)
Figure 152 Market participant categorization
Figure 153 Company market position analysis
Figure 154 Estimated company market share analysis, 2022 (%)
Figure 155 SWOT - Accenture
Figure 156 SWOT - Linical Americas
Figure 157 SWOT - IQVIA
Figure 158 SWOT - Cognizant
Figure 159 SWOT - Laboratory Corporation of America Holdings
Figure 160 SWOT - IBM Corporation
Figure 161 SWOT - ArisGlobal
Figure 162 SWOT - ICON plc
Figure 163 SWOT - Capgemini
Figure 164 SWOT - ITClinical
Figure 165 SWOT - Take Solutions
Figure 166 SWOT - Parexel International Corporation
Figure 167 SWOT - Clario
Figure 168 SWOT - Wipro
Figure 169 SWOT - United BioSource LLC
Figure 170 SWOT - FMD K&L
Figure 171 Commonly outsourced PV activities
Figure 172 Vendor selection criteria